WallStreetZenWallStreetZen

NASDAQ: OTLK
Outlook Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for OTLK

Based on 7 analysts offering 12 month price targets for Outlook Therapeutics Inc.
Min Forecast
$30.00+324.33%
Avg Forecast
$50.20+610.04%
Max Forecast
$100.00+1,314.43%

Should I buy or sell OTLK stock?

Based on 7 analysts offering ratings for Outlook Therapeutics Inc.
Strong Buy
Strong Buy
4 analysts 57.14%
Buy
3 analysts 42.86%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their OTLK stock forecasts and price targets.

OTLK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-17
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-02-15
lockedlocked$00.00+00.00%2024-01-25
lockedlocked$00.00+00.00%2024-01-25
Ascendiant Capital
Bottom 3%
3
BuyMaintains$40.00+465.77%2023-12-29
Capital One Financial
Top 4%
97
BuyUpgrades$100.00+1,314.43%2023-12-27

1 of 1

Forecast return on equity

Is OTLK forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.85%

Forecast return on assets

Is OTLK forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

OTLK revenue forecast

What is OTLK's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.4M
Avg 2 year Forecast
$9.6M
Avg 3 year Forecast
$57.0M

OTLK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OTLK$7.07$50.20+610.04%Strong Buy
OPT$2.84N/AN/A
ADVM$7.92$34.40+334.34%Strong Buy
PRQR$1.95$3.17+62.41%Buy
KOD$3.18$3.33+4.81%Strong Sell
View Top Biotech Stocks

Outlook Therapeutics Stock Forecast FAQ

Is Outlook Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: OTLK) stock is to Strong Buy OTLK stock.

Out of 7 analysts, 4 (57.14%) are recommending OTLK as a Strong Buy, 3 (42.86%) are recommending OTLK as a Buy, 0 (0%) are recommending OTLK as a Hold, 0 (0%) are recommending OTLK as a Sell, and 0 (0%) are recommending OTLK as a Strong Sell.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.

What is OTLK's revenue growth forecast for 2024-2026?

(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Outlook Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast OTLK's revenue for 2024 to be $33,470,061, with the lowest OTLK revenue forecast at $33,470,061, and the highest OTLK revenue forecast at $33,470,061. On average, 4 Wall Street analysts forecast OTLK's revenue for 2025 to be $225,279,256, with the lowest OTLK revenue forecast at $88,941,421, and the highest OTLK revenue forecast at $359,744,641.

In 2026, OTLK is forecast to generate $1,334,963,912 in revenue, with the lowest revenue forecast at $1,183,154,950 and the highest revenue forecast at $1,584,795,681.

What is OTLK's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: OTLK) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is OTLK's Price Target?

According to 7 Wall Street analysts that have issued a 1 year OTLK price target, the average OTLK price target is $50.20, with the highest OTLK stock price forecast at $100.00 and the lowest OTLK stock price forecast at $30.00.

On average, Wall Street analysts predict that Outlook Therapeutics's share price could reach $50.20 by May 17, 2025. The average Outlook Therapeutics stock price prediction forecasts a potential upside of 610.04% from the current OTLK share price of $7.07.

What is OTLK's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: OTLK) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.